Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic.

ABSTRACT: Prostate cancer (PC) is the second most common cancer in men worldwide. Due to the large-scale sequencing efforts, there is currently a better understanding of the genomic landscape of PC. The identification of defects in DNA repair genes has led to clinical studies that provide a strong rationale for developing poly (ADP-ribose) polymerase (PARP) inhibitors and DNA-damaging agents in this molecularly defined subset of patients. The identification of molecularly defined subgroups of patients has also other clinical implications; for example, we now know that carriers of breast cancer 2 (BRCA2) pathogenic sequence variants (PSVs) have increased levels of serum prostate specific antigen (PSA) at diagnosis, increased proportion of high Gleason tumors, elevated rates of nodal and distant metas

SUBMITTER: Ghose A 

PROVIDER: S-EPMC8471942 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature